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Breast cancer is a leading cause of female deaths worldwide. In Malaysia, it is the most common form of female cancer while
Inﬁltratingductalcarcinoma(IDC)isthemostcommonformofbreastcancer.Aproteomicapproachwasusedtoidentifychanges
in the protein proﬁle of breast cancerous and normal tissues. The patients were divided into diﬀerent cohorts according to tumour
stage and grade. We identiﬁed twenty-four diﬀerentially expressed hydrophilic proteins. A few proteins were found signiﬁcantly
related to various stages and grades of IDC, amongst which were SEC13-like 1 (isoform b), calreticulin, 14-3-3 protein zeta, and
14-3-3 protein eta. In this study, we found that by deﬁning the expression of the proteins according to stages and grades of IDC, a
signiﬁcant relationship between the expression of the proteins with the stage or grade of IDC can be established, which increases
the usefulness of these proteins as biomarkers for IDC.
1.Introduction
Breast cancer is the major form of female cancer that is
responsible for 548,000 deaths or 7% of all cancer deaths in
women[1,2].InMalaysia,breastcanceristhemostcommon
formofcancerinallagegroupsofwomen[3]andInﬁltrating
ductal carcinoma (IDC) is the most common form of breast
cancer that made up ∼85% of all breast cancer cases [4].
Over these years, progress has been made on the study of
molecular pathways, including the roles of hormones and
receptors in cancer development and progression. However,
the exact roles these molecules play in breast cancer growth
remaininconclusiveandpoorlyunderstood[5,6].Therefore,
identifying the diﬀerentially expressed proteins in breast
cancer would be useful in understanding how the disease
forms and advances. Identiﬁcation of these proteins would
also enable treatments that are speciﬁc to breast cancer to be
formulated.
Proteomics is a large-scale study of the proteome, which
is the entire compliment of expression of proteins by a living
organism[7].Proteomicsusestoolssuchastwo-dimensional
polyacrylamide gel electrophoresis (2D-PAGE) and liquid
chromatography/massspectrometry(LC/MS)[8]forpr otein
separation and analysis, respectively. This approach has been
used to identify protein biomarkers in breast cancers [9–13]
and other types of cancer [14–17]. Identiﬁcation of protein
biomarkers may have important prognostic values in the
diagnosis and treatment of the disease [18, 19].
The classiﬁcation and prognosis of breast cancer are
based on stage and grade of the tumour [20, 21]. Both the
informationforgradeandstageofthecancerareusedtoplan
treatment for the patient. In this study, we aim to identify
thediﬀerentiallyexpressedaqueoussolubleproteinsbetween
cancerous and normal IDC breast tissues and to relate the
expression of these proteins to the grade and stage of IDC.
We believe this information will contribute to the prognosis
of IDC breast cancer.
2. Methods
2.1. Breast Cancer Patients. Breast cancer patients were
diagnosed with IDC and had undergone surgical treatment2 Journal of Biomedicine and Biotechnology
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Figure 1: (a) 2D gel image of TRIS extract from (i) normal and (ii) cancer breast tissues of same patient. (b) Protein spot intensity of (i)
calreticulin and (ii) 14-3-3 protein zeta from normal and cancerous tissue of same patient.
at Penang General Hospital, Penang, Malaysia. The patients
were divided by stage and grade into 4 cohorts; Stages
II, III and Grades II, III, respectively. Stage II, III cohorts
contained 7 patients and 10 patients, respectively while
Grade II and III cohorts contained 7 patients and 9 patients,
respectively. Each sample set comprised cancerous and
normal tissues from the same patient. The tissues were
conﬁrmed as cancerous and normal, respectively, by the
hospital’s pathologist. The information on patients’ age,
stage, TNM, grade, estrogen receptor, progesterone receptor,
and C-ERB-B2 oncoprotein status is listed in Table 1.
2.2. Tissue Samples. Human ethical clearance from the
Human Ethical Clearance Committee of Universiti Sains
Malaysia and the Ministry of Health, Malaysia was received
prior to conducting the study. Normal and cancerous breast
tissues samples from IDC patients were obtained from
the Penang General Hospital, Penang, Malaysia. Informed
consents from the breast cancer patients were received
before the tissues were collected. The breast tissues were
pathologically conﬁrmed by the hospital’s pathologists.
Breast carcinoma tumour tissues were taken from the ductal
epithelium. Frozen section of tissue morphology was takenJournal of Biomedicine and Biotechnology 3
Table 1: Patient information.
Patient no. Age Stage TNM Grade Estrogen receptor Progesterone receptor C-ERB-B2 oncoprotein
15 4 3 T 2N1Mx 1 Positive Positive Negative
26 7 2 T 2N0Mx 3 Negative Negative Negative
36 0 3 T 2N1Mx 2 Positive Positive Positive
47 4 3 T 2N1Mx 2 Positive Positive Negative
56 7 3 T 3N1Mx 2 Negative Negative Positive
67 8 3 T 4N1Mx 3 Positive Positive Negative
76 4 3 T 3N1Mx 3 Negative Negative Positive
86 3 2 T 2N0Mx 3 Positive Negative Positive
96 5 2 T 2N1Mx 3 Negative Negative Negative
10 59 2 T2N1Mx 3 Negative Negative Negative
11 55 4 T4NxM1 3 Positive Negative Negative
12 72 2 T2N0Mx 2 Positive Negative Negative
13 80 3 T3N1Mx 2 Positive Positive Negative
14 60 2 T2N1Mx 3 Negative Negative Negative
15 62 2 T2N1Mx 3 Negative Negative Positive
16 — 3 T4BN1Mx 1 Positive Positive Positive
17 54 3 T2N2Mx 2 Negative Negative Negative
18 64 3 T3N0Mx 2 Positive Positive Negative
from the cancerous tissues from the anterior and deep
region to ensure tumour adequacy and only the part of the
cancerous tissue that had greater than 90% malignant cells
was used in this study. Tissues were stored at −80◦Cp r i o rt o
analysis.
2.3. Protein Extraction. Frozen tissues were thawed at room
temperature (25◦C), rinsed with distilled water and homog-
enized on ice for 5min. Proteins were extracted by addition
of Tris buﬀer (TRIS) ((40mM Tris, 1mM 4-(2-Aminoethyl)
benzenesulfonyl ﬂuoride (AEBSF)) to the homogenized
tissue. After centrifugation (13000rpm, 20min, 20◦C), the
supernatant was collected and the protein concentration was
determined in duplicates by RC-DC protein assay (Bio-Rad,
USA).
2.4. Protein Preparation. Prior to isoelectric focusing,
TRIS protein extracts were ﬁrst precipitated by using
trichloroacetic acid (TCA)/acetone method [22]. Ten
percent TCA in ice-cold acetone containing 20mM
dithiothreitol (DTT) was added to the TRIS extracts
and incubated at −20◦C for 1.5h. After centrifugation
(13000rpm, 15min, 4◦C), the pellet was washed with
ice-cold acetone containing 20mM DTT before being
centrifuged (13000rpm, 15min, 4◦C). The supernatant was
discarded and the pellet was resolubilized in thiourea lysis
buﬀer (TLB) (8M Urea, 2M Thiourea, 4% (w/v) 3-[(3-
Cholamidopropyl)dimethylammonio]-1-propanesulfonate
(CHAPS), 0.4% (w/v) carrier ampholyte, 50mM DTT,
1mM AEBSF) and incubated for 1h at 25◦C.
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Figure 2: Protein spots selected for in-gel digestion.
2.5. 2D-Gel Electrophoresis. A protein extract containing
250mg protein was passively rehydrated unto an 11cm pH
4-7 IPG strips (Bio-Rad, USA) for 15h at 20◦C. Isoelectric
focusing (IEF) was performed using the Protean IEF Cell
(Bio-Rad, USA) at 20◦C for 15min at 250V, 2.5h at
8000V and held at 8000V for 30kVh. The proteins were
equilibrated by adding in equilibration buﬀer I (6M Urea,4 Journal of Biomedicine and Biotechnology
Table 2: Identity and properties of twenty-four diﬀerentially expressed proteins.
Protein spot
no.
SwissProt
Accession
Number
Protein name Molecular class Molecular
weight (Da)
Isoelectric
point (pI)
GRAVY
score
MOWSE
score
Sequence
coverage (%)
1 P02768 Serum albumin
precursor Transport/cargo 71397 5.92 −0.354 96 14
2 P00441 Superoxide
dismutase Oxidoreductase 16168 5.70 −0.344 52 9
3 P32119 Peroxiredoxin-2 Oxidoreductase 21935 5.67 −0.199 260 26
4 P00739
Haptoglobin-
related
precursor
Transport/cargo 39529 6.42 −0.308 43 3
5 P02766 Transthyretin
precursor Transport/cargo 16003 5.52 −0.029 75 22
6 P15090 Fatty acid binding
protein Carrier protein 14704 6.81 −0.249 223 24
7 P00738
Haptoglobin
precursor, allele 2
(validated)
Transport/cargo 45901 6.13 −0.421 56 6
8 P02768
Serum albumin
precursor
(validated)
Transport/cargo 69366 5.92 −0.354 46 4
9 P00739
Haptoglobin-
related protein
precursor
Transport/cargo 39529 6.42 −0.308 55 3
10 P09211 Glutathione
transferase Transferase 23464 5.42 −0.121 277 53
11 P68371 Class IV beta
tubulin
Structural
protein 50217 4.82 −0.362 52 13
12 P55735 SEC13-like 1,
isoform b Transport/cargo 36062 5.22 −0.372 115 37
13 P02675 Fibrinogen beta
chain precursor
Coagulation
factor 56624 8.54 −0.758 87 28
14 P02675 Fibrinogen beta
chain precursor
Coagulation
factor 56624 8.54 −0.758 134 31
15 P27797 Calreticulin Calcium
binding protein 47092 4.30 −1.104 107 29
16 Not available Unidentiﬁed
protein N/A N/A
∗ N/A N/A N/A N/A
17 Q63610 Hypothetical
protein
Hypothetical
protein 27407 4.71 −0.992 59 27
18 P63104 14-3-3 protein zeta
(kinase regulator)
Adaptor
molecule 27745 4.73 −0.621 193 47
19 Q04917 14-3-3 protein eta Adaptor
molecule 28244 4.76 −0.618 71 23
20 P52907 F-actin capping
protein
Cytoskeletal
protein 32965 5.45 −0.668 53 26
21 P02766 Transthyretin
precursor Transport/cargo 16003 5.52 −0.029 85 22
22 P68133 Actin alpha Cytoskeletal
protein 38172 5.39 −0.161 64 17
23 P07195 L-lactate
dehydrogenase Dehydrogenase 36928 5.71 0.056 222 34
24 P21695
Glycerol-3-
phosphate
dehydrogenase
Dehydrogenase 38206 5.81 0.106 312 51Journal of Biomedicine and Biotechnology 5
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Figure 3: Identiﬁcation of protein. (a) Full scan MS spectrum of peptide eluted out at 32.4 minutes. (b) MS/MS spectrum of 610.4 product
ions. (c) Amino acid sequence of peptide eluted out 32.4 minutes.
0.375M Tris-HCl, pH 8.8, 2% SDS, 20% glycerol, 1%
(w/v) DTT) to the focused IPG strip for 10min at 25◦C,
followed by the addition of equilibration buﬀer II (6M Urea,
0.375M Tris-HCl, pH 8.8, 2% SDS, 20% glycerol, 2.5%
(w/v) iodoacetamide) for 10min at 25◦C. The IPG strip
was positioned on top of a 10% sodium dodecyl sulfate-
polyacrylamide gel (SDS-PAGE) (135 × 160 × 1mm) and
electrophorised in a PROTEAN II xi Cell (Bio-Rad, USA)
at a constant voltage of 200V for 3 hours according to
the method of Laemmli [23]. After electrophoresis, the gels
were stained using Coomassie Brilliant Blue 250 (CBR-
250) solution (0.1% (w/v) CBR-250, 40% (v/v) methanol,
10% (v/v) acetic acid) for 4h. The staining background
was removed by incubating the gel in a destaining solution
(40% (v/v) methanol, 2% (v/v) acetic acid) twice for 2h
each.
2.6. Gel Imaging and Analysis. The images of 2D-PAGE
gels were captured by using Versadoc system (Bio-Rad,
USA). The gel images were processed and analyzed by using
PDQuest software 7.3 (Bio-Rad, USA). The software created
a match set to compare the images of cancerous and normal
breast tissues, which was then used to analyze quantitative
and qualitative diﬀerences in protein spots between the
images. Each protein spot was normalized by dividing the
spot intensity with the total intensity value of all the pixels
in the gel image in order to quantitate the spot and to
correct slight variations in protein loading. A protein was
consideredasup-regulatedifitsexpressionlevelincancerous
tissues was increased 1.5-fold or more as compared to
normal breast tissue: it was considered as down-regulated if
its expression level in cancerous tissues was decreased 1.5-
fold or more as compared to the normal breast tissue. The6 Journal of Biomedicine and Biotechnology
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Figure 4: Immunoblot of annexin V. Lane M: protein molecular
weight markers (in kDa). Lane 1: normal TRIS extract from ﬁrst
patient. Lane 2: cancer TRIS extract from ﬁrst patient. Lane 3:
normal TRIS extract from second patient. Lane 4: cancer TRIS
extract from second patient.
statistical signiﬁcance of the protein’s diﬀerential expression
was determined by using the Wilcoxon signed-rank test
available in the PDQuest software.
2.7. In Gel Digestion and Liquid Chromatography Tandem
Mass Spectrometry (LC/MS/MS) Analysis. In gel digestion
was performed according to Othman et al. [24]. Brieﬂy,
protein spots of interest were excised from the gel. They
were washed with deionized water, cut in ﬁne pieces,
hydrated and dehydrated with 100mM ammonium bicar-
bonate (NH4HCO3) and acetonitrile (ACN), respectively, in
order to remove the stain material. The protein was reduced
in situ with DTT and alkylated with iodoacetamide and
ﬁnally digested into peptides by treating it with trypsin. The
tryptic peptides were eluted from the gel and dried under the
continuous ﬂow of nitrogen gas. Peptides were reconstituted
in 30μL of 0.1% (v/v) formic acid in a solution of deionized
water:acetonitrile (85:15) and were fractionated by RP-
HPLC (C18, 150 × 0.3mm, 5μm 300 ˚ A) using an Agilent
1100 Series. The mobile phases A (0.1% formic acid in
deionized water) and B (0.1% formic acid in ACN) are
pumped at a constant ﬂow rate of 4μL/min. The peptides
were eluted by a linear gradient of 5% B to 95% B in
70min and held constant at 95% B for 5min. The HPLC
was interfaced to an ESI-ion trap mass analyzer (Agilent).
Two types of scan were performed: full scan MS and full
scan MS/MS, where the two most intense ions in an MS
scan that exceeded the set threshold of 5000 counts will
be isolated for MS/MS scan to produce a series of product
ions spectrum for protein identiﬁcation. The instrumental
parametersusedwereNebulizerpressureat20.0psi,auxiliary
dry gas ﬂow of 6.0L/min, auxiliary dry gas temperature
at 300◦C, capillary voltage at 3.5kV, exit capillary voltage
84.5V, skimmer 1 voltage at 17.2V, skimmer 2 voltage at
6.0V. MS scan region from 200–1800m/z with a scan time
1s and a interscan time of 0.1s. The MS/MS scan parameters
were Default collision energy (voltage) of 1.15V, charge state
of 2, minimum threshold of 5000 counts, and isolation
widthof2m/z.Proteinidentiﬁcationwasdonebysubmitting
the MS/MS data to a MASCOT database search engine at
http://www.matrixscience.com/. The search parameters used
were Homo sapiens for taxonomy, carboxymethyl for ﬁxed
modiﬁcations, peptide tolerance of ±2Da, MS/MS tolerance
of ±0.8Da, and average experimental mass value.
2.8. Western Blotting. Western blotting was carried out
using a semidry method according to Lauriere [25]. Protein
extracts were separated by one-dimensional SDS-PAGE
according to Laemmli [23]. The gel was incubated in a cold
transfer buﬀer (25mM Tris, 192mM Glycine and 1.3mM
SDS, pH 8.3) for 30min. The proteins were transferred from
the gel to a nitrocellulose membrane (Bio-Rad, USA) in a
TE 70 Semiphor semidry transfer unit (Hoefer Scientiﬁc,
Germany)at134mAfor1.5h.Themembranewasincubated
with blocking buﬀer (3% (w/v) bovine serum albumin
(BSA) in phosphate buﬀered saline (PBS)) for 2h at 25◦C.
After washing with PBS, the membrane was incubated in
20mL of mouse antiannexin V antibody (Abnova, Taiwan)
with a 1:2000 dilution in antibody diluent buﬀer (0.1%
(w/v) BSA, 0.1% Tween 20, 0.02% sodium azide in PBS)
overnight at 25◦C. After PBS washing, the membrane
was incubated in 50mL of horseradish peroxidase (HRP)
conjugated anti-mouse secondary antibody (Bio-Rad, USA)
at 1:3000 dilution for 2h at 25◦C. After being washed with
PBS, 20mL of 4-Chloro naphthol (4CN), substrate solution
(Bio-Rad, USA) was added to the membrane until the band
is visualized.
3. Results
In this study, similar amount of protein and identical separa-
tion and staining conditions were applied to all the samples.
Although the pattern of the 2D images for cancerous and
normal breast tissues was relatively similar, the intensities of
the spots varied between the tissues types. Figure 1 shows
examples of 2D images of cancerous and normal tissues
obtained from the same patient. The diﬀerence in spots
intensities indicates the diﬀerentially expressed proteins
between the cancerous and normal tissues, these spots were
excised and subjected to mass spectrometry analysis for
protein identiﬁcation. These spots are shown in Figure 2.Journal of Biomedicine and Biotechnology 7
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Figure 5: Distribution of proteins in TRIS extracts of all patients. The expression of proteins was deﬁned as upregulation, downregulation,
equal expression, and nonexpression in each patient.
A total of 24 diﬀerentially expressed protein spots were
subjected to further analysis and the protein identities
were listed in Table 2. The grand average of hydropathy
(GRAVY) scores indicate the polarity of the proteins, the
more negative the score represents the higher hydrophilicity
of the protein. Figure 3 shows the MS and MS/MS spectra
of one of the proteins. After being subjected to MASCOT
protein database search, the peptide was found to belong to
annexin V; the identity of the protein was further conﬁrmed
by western blotting experiment shown in Figure 4.O u to f
the 24 proteins, four proteins were up-regulated while one
protein was down-regulated in >75% of patients tested.
The up-regulated proteins was SEC13-like 1 (isoform b),
calreticulin, 14-3-3 protein zeta and 14-3-3 protein eta. The
down-regulated protein was ﬁbrinogen beta chain precursor.
The Wilcoxon signed-rank test was used to determine the
statistical signiﬁcance of the changes in protein expression
levels between the two tissues types. The diﬀerential expres-
sion of these proteins were statistically signiﬁcant with a
95% conﬁdence level (P<. 05). The expression levels of
the rest of the proteins identiﬁed were inconsistent between
patients, where their expression levels range from 6% to
67% variation. We did not detect any unique protein from
cancerous or normal tissues. Figure 5 shows the expression
levels of the 24 proteins in all the patients; the expression
levels were categorized as upregulation, equal expression,
downregulation or nonexpression in the patients tested.
Nineup-regulatedproteinsandonedown-regulatedpro-
teins were detected at a signiﬁcant level (P<. 05) in >70% of
t h eS t a g eI Ip a t i e n t s( n = 7). The proteins that up-regulated
were superoxide dismutase, peroxiredoxin-2, serum albumin
precursor, class IV beta tubulin, SEC13-like 1 (isoform b),
calreticulin, unidentiﬁed protein, 14-3-3 protein zeta and
14-3-3 protein eta while ﬁbrinogen beta chain precursor
was signiﬁcantly down-regulated. Haptoglobin precursor
which was down-regulated in >70% stage II patients was
not statistically signiﬁcant. In contrary, Hypothetical protein
(protein spot 16) was down-regulated in <70% of Stage II
patients,butthechangeinitsexpressionlevelwasstatistically
signiﬁcant. Figure 6 shows the percentage of upregulation,
equal expression, downregulation and nonexpression of the
proteins in Stage II patients.8 Journal of Biomedicine and Biotechnology
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Figure 6: Distribution of proteins in Stage II patients.
Four proteins were up-regulated and one protein was
down-regulated signiﬁcantly (P>. 05) in >70% of the Stage
III patients (n = 10) tested. These up-regulated proteins
were SEC13-like 1 (isoform b), calreticulin, 14-3-3 protein
zeta and 14-3-3 protein eta, while the down-regulated
protein was ﬁbrinogen beta chain precursor. Glutathione
transferase was up-regulated in >70% of Stage III patients
but the change in its expression level was not statistically
signiﬁcant. On the other hand, superoxide dismutase, serum
albuminprecursor,classIVbetatubulin,andF-actincapping
protein were up-regulated in <70% of Stage III patients,
however, their upregulations were statistically signiﬁcantly in
Stage III patients. Haptoglobin precursor was signiﬁcantly
down-regulated in <70% of Stage III patients. Figure 7
shows the percentage of upregulation, equal expression,
downregulation and nonexpression of the proteins for Stage
III patients.
Five proteins were signiﬁcantly (P<. 05) up-regulated
in >70% of the Grade II patients (n = 7). These proteins
were superoxide dismutase, class IV beta tubulin, SEC-like
1 (isoform b), calreticulin and F-actin capping protein.
Glutathione transferase, 14-3-3 protein zeta, and 14-3-3
protein eta were up-regulated in >70% of Grade II patients
but their upregulation was not statistically signiﬁcant. On
contrary, peroxiredoxin-2 was signiﬁcantly up-regulated in
<7 0 %o fG r a d eI Ip a t i e n t s .Figure 8 shows the percentage of
upregulation, equal expression, downregulation and nonex-
pression of the proteins in Grade II patients.
Seven up-regulated proteins and one down-regulated
proteins were signiﬁcantly expressed in >70% of Grade
III patients (n = 9). The up-regulated proteins were
peroxiredoxin-2, SEC-like 1 (isoform b), calreticulin,
unidentiﬁed protein, hypothetical protein, 14-3-3 protein
zeta and 14-3-3 protein eta whilethedown-regulated protein
was ﬁbrinogen beta chain precursor. Additionally, superox-
ide dismutase, serum albumin precursor and class IV beta
tubulin were signiﬁcantly up-regulated while haptoglobin
precursor was signiﬁcantly down-regulated in <70% ofJournal of Biomedicine and Biotechnology 9
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Figure 7: Distribution of proteins in Stage III patients.
Grade III patients. Figure 9 shows the percentage of upregu-
lation, equal expression, downregulation and nonexpression
of the proteins in Grade III patients.
There were 12 proteins that were up-regulated signif-
icantly in at least one of the stage and grade. Figure 10
shows the upregulation of these proteins in stage II, stage
III, grade II, and grade III patients. Superoxide dismutase
was up-regulated at 71% in stage II and grade II patients
and at 60% in stage III and grade III patients. Peroxiredoxin-
2 was up-regulated at 86% in stage II patients and at 50%,
57% and 50% in stage III, grade II and grade III patients,
respectively. Serum albumin precursor was up-regulated at
86% in stage II patients and at 50%, 57% and 67% in stage
III, grade II and grade III patients, respectively. Glutathione
transferase was up-regulated at 70% and 71% in stage III
and grade II patients, respectively. Its upregulation in stage
II and grade III patients were 57% and 67%, respectively.
Class IV beta-tubulin was up-regulated at 71% in both stage
II and grade II patients and at 50% and 67% in stage III
and grade III patients, respectively. SEC13-like 1 was up-
regulated at 71%, 90%, 86% and 78% in stage II, III, grade II
and III patients, respectively. Calreticulin was up-regulated
at 86%, 100%, 100% and 89% in stage II, III, grade II and
III patients, respectively. The unidentiﬁed protein (protein
spot 16) was up-regulated at 86% and 78% of stage II
and grade III patients, respectively and at 50% and 57%
in stage III and grade II patients, respectively. Hypothetical
protein was up-regulated at 78% in grade III patients and
at 57%, 60% and 43% in stage II, III and grade II patients,
respectively. 14-3-3 protein zeta was up-regulated in all
stage and grade groups at 100%, 80%, 71% and 100% in
stage II, III, grade II and III patients, respectively. 14-3-
3 protein eta was up-regulated in 85%, 80% and 100% of
stage II, III and grade III patients, respectively. However,
its upregulation in grade II patients was only 57%. F-actin
capping protein was up-regulated at 85% in grade II patients
and at 57%, 60% and 56% in stage II, III and grade III
patients, respectively.10 Journal of Biomedicine and Biotechnology
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Figure 8: Distribution of proteins in Grade II patients.
4. Discussion
Tissues heterogeneity is the main problem encountered
when conducting proteomic analysis on tissue specimens.
In this study, only the part of cancerous tissues with
>90% malignancy was used to ensure tumour adequacy. We
used the normal tissue adjacent to the tumour tissue for
comparison purpose, we found that this is crucial due to
tissue heterogeneity between patients, although there was a
consistent protein proﬁles obtained from the patients, the
proﬁles were not identical. This can be explained as proteins
are expression components of cells, and therefore they will
be expressed diﬀerently under diﬀerent environment which
caused as variations between tissues from diﬀerent patients;
therefore, the best comparison for protein expression would
be between the cancerous and normal tissues from the same
patients. Despite this, the drawback of using such normal
tissues as the control is that these tissues may possess some
molecular and epigenetic abnormalities. We overcome this
problem by only collecting the normal tissues that were
conﬁrmed normal by pathologist; a minute contamination
that derived from tissue abnormalities would be excluded
as the minute proteins derived from the abnormal tissues
would not be detected under Commassie blue staining.
In addition, we focused only on the proteins that showed
consistent expression in the patients in order to minimize
false identiﬁcation of protein that resulted from tissue
heterogeneity between patients or sample handling (Seng et
al. [26]). Furthermore, normalization of the gel intensity was
carried out prior to the determination of the target protein
spots intensities, where the intensity of each protein spot was
calculated as the percentage to the total intensity of all the
spots on the same image. This approach was taken to reduce
the variation in protein spot intensity that may be caused
by variability in sample loading. The main limitation of this
study is the number of tissues used, nevertheless, potentialJournal of Biomedicine and Biotechnology 11
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Figure 9: Distribution of proteins in Grade III patients.
biomarkers with consistent and signiﬁcant upregulation in
patients were identiﬁed that worth further investigation with
a greater number of tissues.
Sinceproteinsarethefunctionalcomponentsofcellsthat
regulate cell’s activity, it would be interesting to relate the
expression of the diﬀerentially expressed proteins with the
various stages and grades of tumour. We have identiﬁed a
few proteins that can be strongly and signiﬁcantly related
with certain stages and grades of IDC. 14-3-3 protein zeta
was found up-regulated signiﬁcantly (P<. 05) in all (100%)
the patients with grade III cancer and also in all the patients
withstageIIcancerwhile14-3-3proteinetawasdetectedup-
regulated signiﬁcantly in all (100%) the grade III patients
tested. Calreticulin was found to be a good biomarker for
all the grades and stages tested in this study, where its
expression levels were 100% in grade II patients and also
stage III patients, respectively, and as for grade III patients
and stage II patients, its expression levels were greater than
80% in both the two cohorts. Other proteins with >80%
expression levels in grade II patients were F-actin capping
protein and SEC13-like 1 protein. In stage III patients,
14-3-3 protein eta, 14-3-3 protein zeta and SEC13-like 1
were expressed at ≥80%. 14-3-3 protein eta, an unidentiﬁed
protein (60kDa), calreticulin, serum albumin precursor and
peroxiredoxin-2 were expressed at >80% in stage II patients.
In general, we have identiﬁed four proteins that can be
strongly and signiﬁcantly related to at least one of the stages
or grades tested in this study, these proteins were SEC13-like
1, calreticulin, 14-3-3 protein zeta and 14-3-3 protein eta.
There was an interesting trend of expressions shown by
these four proteins, whereby both the 14-3-3 protein eta and
zeta were shown to be strongly related with grade III patients
and stage II patients indicating that the proteins may be
associated with the aggressiveness of the tumour before the
tumour spread. On the other hand, calreticulin and SEC13-
like 1 were related more strongly with grade II patients and
stage III patients indicating that as the tumour has spread to
lymph nodes, the expression of these proteins increases.12 Journal of Biomedicine and Biotechnology
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Figure 10: Comparison of up-regulated proteins in Stage II, Stage III, Grade II and Grade III patients.
Besides stage and grade, the expression levels of a few
r e c e p t o r ss u c ha sp r o g e s t e r o n e ,e s t r o g e na n dC - E R B - B 2 and
the combinations of the three receptors as triple positive and
triple negative grading were also used in the prediction of
the prognosis of the disease. In this study, we found that
within the stages and grades tested, the expressions of the
four proteins were not correlated with the expressions of
these receptors (see supplementary material available online
at doi: 10.1155/2010/516469).
Calreticulin is a 48kDa multifunctional calcium ion-
binding protein that regulates cellular activities in the
endoplasmic reticulum (ER) [27]. It binds to misfolded
proteins to prevent them from being transported to the
Golgi apparatus. Calreticulin has been reported to be highly
expressed in human breast ductal carcinoma cells compared
to normal breast cells [28–30].
14-3-3 eta protein (YWAH) and 14-3-3 zeta protein
(YWAZ) are subunits of the 14-3-3 isoform proteins (14-
3-3). These proteins bind to proteins which are involved in
thesignaling pathway,including kinases andtransmembrane
receptors. 14-3-3 interact with signaling proteins to regulate
a wide variety of cellular events [31–35]. 14-3-3 regulate
cancer-related processes, where they inhibit apoptosis, act
as cell cycle checkpoints [36, 37] and control oncogene
products that are overexpressed in cancer cells [38]. 14-3-3
were up-regulated in breast ductal carcinoma tumour cells
[39].
Protein SEC13 homolog (SEC13) belongs to the SEC13
family of WD-repeat proteins. SEC13 is required in the
production of vesicles from the ER to the Golgi apparatus
for the transport of proteins [40]. Its involvement in cancer
has not yet been reported.
Serum albumin precursor is used for the synthesis of
Human serum albumin (HSA), an endogenous plasma
protein and it is the main component of the blood transport
system. HSA transports and binds with water, hormones,
fatty acids, metal ions and drugs. It also maintains blood
osmotic pressure and pH besides acting as antioxidantJournal of Biomedicine and Biotechnology 13
in removing reactive oxygen species in the blood plasma
[41]. Nevertheless, HSA levels and characteristics in cancer
cells might have been modiﬁed from normal HSA [42].
The albumin portion of HSA exerts a growth inhibition
in breast cancer cells that may aﬀect cell proliferation by
modulating the activities of growth factors [43]. HSA was a
potentstimulatorofestronesulphataseactivityandtherefore
contributes directly to the high estrogen concentrations
found in breast cancer [44]. In addition to breast cancer,
HSA was found accumulated in tumours in ovarian cancer
[45].
5. Conclusion
The major limitation of this study is its sample size, never-
theless, the proteins identiﬁed were found consistently up-
regulated in the patients tested and their upregulations were
signiﬁcant statistically (P<. 05) indicating their possible
roles in the development of the disease. The expressions
levels of SEC13-like 1 (isoform b), calreticulin, 14-3-3
protein zeta, and 14-3-3 protein eta were found signiﬁcantly
related to certain stages or grades of the IDC breast tumour
tissues. In view of their consistent (100%) upregulated
expression in speciﬁc stage or grade of IDC breast tumour,
their potential use as biomarkers for diagnosis, prognosis, or
treatment of IDC breast cancer is undeniable.
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IDC: Inﬁltrating ductal carcinoma
2D-PAGE: Two-dimensional polyacrylamide gel
electrophoresis
AEBSF: 4-(2-Aminoethyl) benzenesulfonyl ﬂuoride
TCA: Trichloroacetic acid
DTT: Dithiothreitol
CHAPS: 3-[(3-Cholamidopropyl)dimethylammonio]-
1-propanesulfonate
SDS-PAGE: Sodium dodecyl sulfate polyacrylamide gel
electrophoresis
CBR-250: Coomassie Brilliant Blue 250
LC/MS/MS: Liquid chromatography tandem mass
spectrometry
ACN: Acetonitrile
NH4HCO3: Ammonium bicarbonate
BSA: Bovine serum albumin
PBS: Phosphate buﬀered saline
HRP: Horseradish peroxidase
4CN: 4-chloro napthtol.
Acknowledgments
The authors thank the Ministry of Science, Technology
and Innovation Malaysia for providing a Grant (project
no.: 02-01-05-SF0353) to fund this project, the Ministry of
Health,Malaysiaforprovidingthetissues,andhumanethical
clearance for conducting this research.
References
[1] American Cancer Society, “How many women get breast can-
cer?” http://www.cancer.org/docroot/CRI/content/CRI 2 2
1X How many people get breast cancer 5.asp.
[2] World Health Organization, “Cancer: Fact Sheet,” http://www
.who.int/entity/mediacentre/factsheets/fs297/en/index.html.
[3] G. C. C. Lim and Y. Halimah, Second Report of the National
Cancer Registry 2003: Cancer Incidence in Malaysia 2003,
National Cancer Registry, Kuala Lumpur, Malaysia, 2004.
[4] J. G. Molland, M. Donnellan, N. C. Janu, H. L. Carmalt, C. W.
Kennedy, and D. J. Gillett, “Inﬁltrating lobular carcinoma—
a comparison of diagnosis, management and outcome with
inﬁltratingductcarcinoma,”TheBreast,vol.13,no.5,pp.389–
396, 2004.
[5] Y. Peng, Y. Li, L. L. Gellert et al., “Androgen receptor
coactivator p44/Mep50 in breast cancer growth and invasion,”
Journal of Cellular and Molecular Medicine. In press.
[6] R. K. Rasmussen, H. Ji, J. S. Eddes et al., “Two-dimensional
electrophoretic analysis of human breast carcinoma proteins:
mapping of proteins that bind to the SH3 domain of mixed
lineage kinase MLK2,” Electrophoresis, vol. 18, no. 3-4, pp.
588–598, 1997.
[7] M. R. Wilkins, C. Pasquali, R. D. Appel et al., “From
proteins to proteomes: large scale protein identiﬁcation by
two-dimensional electrophoresis and amino acid analysis,”
Bio/Technology, vol. 14, no. 1, pp. 61–65, 1996.
[ 8 ]P .H .O ’ F a r r e l l ,“ H i g hr e s o l u t i o nt w od i m e n s i o n a le l e c -
trophoresis of proteins,” The Journal of Biological Chemistry,
vol. 250, no. 10, pp. 4007–4021, 1975.
[9] C. S. Giometti, S. L. Tollaksen, C. Chubb, C. Williams,
and E. Huberman, “Analysis of proteins from human breast
epithelial cells using two-dimensional gel electrophoresis,”
Electrophoresis, vol. 16, no. 7, pp. 1215–1224, 1995.
[10] F. Le Naour, D. E. Misek, M. C. Krause et al., “Proteomics-
based identiﬁcation of RS/DJ-1 as a novel circulating tumour
antigen in breast cancer,” Clinical Cancer Research, vol. 7, no.
11, pp. 3325–3327, 2001.
[11] D.-Q. Li, L. Wang, F. Fei et al., “Identiﬁcation of breast cancer
metastasis-associated proteins in an isogenic tumor metastasis
model using two-dimensional gel electrophoresis and liq-
uidchromatography-iontrap-massspectrometry,”Proteomics,
vol. 6, no. 11, pp. 3352–3368, 2006.
[12] M. J. Page, B. Amess, R. R. Townsend et al., “Proteomic
deﬁnition of normal human luminal and myoepithelial breast
cells puriﬁed from reduction mammoplasties,” Proceedings
of the National Academy of Sciences of the United States of
America, vol. 96, no. 22, pp. 12589–12594, 1999.
[13] K. Williams, C. Chubb, E. Huberman, and C. S. Giometti,
“Analysis of diﬀerential protein expression in normal and
neoplastic human breast epithelial cell lines,” Electrophoresis,
vol. 19, no. 2, pp. 333–343, 1998.
[14] P. Alfonso, A. N´ u˜ nez, J. Madoz-Gurpide, L. Lombardia, L.
S´ anchez, and J. I. Casal, “Proteomic expression analysis of
colorectal cancer by two-dimensional diﬀerential gel elec-
trophoresis,” Proteomics, vol. 5, no. 10, pp. 2602–2611, 2005.
[ 1 5 ] R .C h e n ,S .P a n ,T .A .B r e n t n a l l ,a n dR .A e b e r s o l d ,“ P r o t e o m i c
proﬁlingofpancreaticcancer forbiomarkerdiscovery,” Molec-
ular and Cellular Proteomics, vol. 4, no. 4, pp. 523–533, 2005.
[16] D. B. Friedman, S. Hill, J. W. Keller et al., “Proteome analysis
of human colon cancer by two-dimensional diﬀerence gel
electrophoresis and mass spectrometry,” Proteomics, vol. 4, no.
3, pp. 793–811, 2004.14 Journal of Biomedicine and Biotechnology
[17] P. R. Jungblut, U. Zimny-Arndt, E. Zeindl-Eberhart et al.,
“Proteomics in human disease: cancer, heart and infectious
diseases,” Electrophoresis, vol. 20, no. 10, pp. 2100–2110, 1999.
[18] M. R. Emmert-Buck, J. W. Gillespie, C. P. Paweletz et al., “An
approach to proteomic analysis of human tumors,” Molecular
Carcinogenesis, vol. 27, no. 3, pp. 158–165, 2000.
[19] F. J. Esteva and G. N. Hortobagyi, “Prognostic molecular
markers in early breast cancer,” Breast Cancer Research, vol. 6,
no. 3, pp. 109–118, 2004.
[20] National Cancer Institute, “Breast cancer staging,” http://www
.cancer.gov/cancertopics/wyntk/breast/page9.
[21] National Cancer Institute, “Tumor grade: questions and
answers,” http://www.cancer.gov/cancertopics/factsheet/De-
tection/tumor-grade.
[22] A. Tsugita and M. Kamo, “2-D electrophoresis of plant
proteins,” in Methods in Molecular Biology, A. J. Link, Ed., vol.
112 of 2-D Proteome Analysis Protocols, pp. 95–98, Humana
Press, Totowa, NJ, USA, 1999.
[23] U. K. Laemmli, “Cleavage of structural proteins during the
assembly of the head of bacteriophage T4,” Nature, vol. 227,
no. 5259, pp. 680–685, 1970.
[24] M. I. Othman, M. I. A. Majid, M. Singh, S. Subathra, L. Seng,
and L.-H. Gam, “Proteomics of Grade 3 inﬁltrating ductal
carcinoma in Malaysian Chinese breast cancer patients,”
BiotechnologyandAppliedBiochemistry,vol.52,no.3,pp.209–
219, 2009.
[25] M. Lauriere, “A semidry electroblotting system eﬃciently
transfers both high- and low-molecular-weight proteins sep-
arated by SDS-PAGE,” Analytical Biochemistry, vol. 212, no. 1,
pp. 206–211, 1993.
[26] S. Liang, M. Singh, and L.-H. Gam, “The diﬀerential
expression of aqueous soluble proteins in breast normal and
cancerous tissues in relation to ethnicity of the patients;
Chinese, Malay and Indian,” Disease Markers, vol. 28, no. 3,
pp. 149–165, 2010.
[27] P. D. Nash, M. Opas, and M. Michalak, “Calreticulin: not
just another calcium-binding protein,” Molecular and Cellular
Biochemistry, vol. 135, no. 1, pp. 71–78, 1994.
[28] L. Bini, B. Magi, B. Marzocchi et al., “Protein expression
proﬁles in human breast ductal carcinoma and histologically
normal tissue,” Electrophoresis, vol. 18, no. 15, pp. 2832–2841,
1997.
[29] K. Chahed, M. Kabbage, B. Hamrita et al., “Detection of pro-
tein alterations in male breast cancer using two dimensional
gel electrophoresis and mass spectrometry: the involvement of
several pathways in tumorigenesis,” Clinica Chimica Acta, vol.
388, no. 1-2, pp. 106–114, 2008.
[30] B. Franz´ en, S. Linder, A. A. Alaiya et al., “Analysis of
polypeptideexpressioninbenignandmalignanthumanbreast
lesions,” Electrophoresis, vol. 18, no. 3-4, pp. 582–587, 1997.
[31] A. Aitken, “14-3-3 and its possible role in co-ordinating
multiplesignallingpathways,”TrendsinCellBiology,vol.6,no.
9, pp. 341–347, 1996.
[ 3 2 ]H .F u ,R .R .S u b r a m a n i a n ,a n dS .C .M a s t e r s ,“ 1 4 - 3 - 3
Proteins: structure, function, and regulation,” Annual Review
of Pharmacology and Toxicology, vol. 40, pp. 617–647, 2000.
[33] P. Russell, “Checkpoints on the road to mitosis,” Trends in
Biochemical Sciences, vol. 23, no. 10, pp. 399–402, 1998.
[34] E. M. C. Skoulakis and R. L. Davis, “14-3-3 Proteins in
neuronal development and function,” Molecular Neurobiology,
vol. 16, no. 3, pp. 269–284, 1998.
[35] M. B. Yaﬀe, “How do 14-3-3 proteins work?—gatekeeper
phosphorylation and the molecular anvil hypothesis,” FEBS
Letters, vol. 513, no. 1, pp. 53–57, 2002.
[36] H. Hermeking, “The 14-3-3 cancer connection,” Nature
Reviews Cancer, vol. 3, no. 12, pp. 931–943, 2003.
[37] G. Tzivion, Z. Luo, and J. Avruch, “A dimeric.14-3-3 protein is
an essential cofactor for Raf kinase activity,” Nature, vol. 394,
no. 6688, pp. 88–92, 1998.
[38] A.-S. Vercoutter-Edouart, J. Lemoine, X. Le Bourhis et al.,
“Proteomic analysis reveals that 14-3-3σ is down-regulated in
human breast cancer cells,” Cancer Research, vol. 61, no. 1, pp.
76–80, 2001.
[39] L.Zang,D .P .T o y ,W .S.H anc ock,D .C.Sgr oi,andB .L.K arger ,
“Proteomic analysis of ductal carcinoma of the breast using
laser capture microdissection, LC-MS, and 16O/18O isotopic
labeling,” Journal of Proteome Research, vol. 3, no. 3, pp. 604–
612, 2004.
[ 4 0 ]B .L .T a n g ,F .P e t e r ,J .K r i j n s e - L o c k e r ,S .H .L o w ,G .G r i ﬃths,
and W. Hong, “The mammalian homolog of yeast Sec13p is
enriched in the intermediate compartment and is essential for
proteintransportfromtheendoplasmicreticulumtotheGolgi
apparatus,” Molecular and Cellular Biology,v o l .1 7 ,n o .1 ,p p .
256–266, 1997.
[41] M.-K. Cha and I.-H. Kim, “Glutathione-linked thiol peroxi-
dase activity of human serum albumin: a possible antioxidant
role of serum albumin in blood plasma,” Biochemical and
Biophysical Research Communications, vol. 222, no. 2, pp. 619–
625, 1996.
[42] A. Gurachevsky, E. Muravskaya, T. Gurachevskaya, L.
Smirnova, and V. Muravsky, “Cancer-associated alteration in
fatty acid binding to albumin studied by spin-label electron
spin resonance,” Cancer Investigation, vol. 25, no. 6, pp. 378–
383, 2007.
[43] I. Laursen, P. Briand, and A. E. Lykkesfeldt, “Serum albumin
as a modulator on growth of the human breast cancer cell line,
MCF-7,” Anticancer Research, vol. 10, no. 2 A, pp. 343–351,
1990.
[44] A. Purohit, D. Y. Wang, M. W. Ghilchik, and M. J. Reed,
“Regulation of aromatase and sulphatase in breast tumour
cells,” Journal of Endocrinology, vol. 150, pp. S65–S71, 1996.
[45] E. F. Petricoin III, A. M. Ardekani, B. A. Hitt et al., “Use of
proteomic patterns in serum to identify ovarian cancer,” The
Lancet, vol. 359, no. 9306, pp. 572–577, 2002.